Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
about
Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDSAntiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profilePharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteersDarunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patientsPhysiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human ImPharmacokinetics and pharmacodynamics of boosted once-daily darunavir.Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In VitroImpact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir.Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.Risk factors contributing to a low darunavir plasma concentration.Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.Combination antiretroviral therapy.
P2860
Q26777251-F3CBCAC6-FA35-4960-B92B-750CA621B085Q28729122-C405A475-5252-4D8F-9656-910DA5764C3AQ33609231-04059498-CDAD-43B5-94F0-C4753C5D4DF2Q33962854-67E1D0E6-7DED-4250-90DC-787E6CE60C83Q34737260-1EED2883-043A-40DE-9269-56A11E026CEDQ35191614-96C05FAB-82F7-4B93-8EFC-300AEEE1C0ECQ35743271-E2A7E058-2333-48CC-87E6-428C813A2462Q36158135-DEB9577E-1611-4247-8ECA-8CC06E741C56Q36599597-5AC9F8DC-04DB-4D9B-BEC6-B0E0F0A8C9D3Q36675900-E98A1013-5BC3-45B4-99EB-92F8DC8A4020Q36785919-5AD49CEE-7219-409A-826C-21DDF3257AFCQ37612932-F1ED0B3B-5AEF-4EED-9B4F-A90CB1848C91Q38222092-D9FEA50C-34A7-4661-AA00-45BD429D0BE0Q38963389-40B9ADF3-3D40-40A3-8966-47C0D85DC053Q39033125-2FECF479-0907-4560-BD4F-142F71238DF0Q40048148-6F711DB3-A96E-494F-BC4F-7A506AC276A5Q40144330-1BEB1A81-8611-4DDC-B0E2-0CBFA3434B18Q40189483-408B0694-C5E2-42F5-B891-367C6A627B47Q40360498-C914962A-6806-45AE-A413-89426D8C5E6CQ41333285-3C1ED9DF-0032-4E49-96BE-F61FB14E5B56Q41696931-7E4BDC49-6A6F-45A4-8787-E082110A91C5Q42199714-5DDB26B2-7396-4293-A532-6A7A1F8DEC12Q42215539-0AA9AA74-1777-4094-8D15-62D50C2AE3A7Q45848326-F1C7A01F-2EB9-4940-A24B-B1CA222EC353Q46106006-609F8DCE-08EF-4F2E-BC19-A4BF3F85CE1BQ47232203-FAD886D0-678C-410E-BCCA-FAA3B4C32362Q47350202-4621F755-81FC-4FE6-86EE-9DA05644EC64Q48500206-14B98E84-EFEC-47CF-A31A-463F17AB6FCBQ50729885-E2325A06-77D1-4AFF-8533-7D0A1980B2BAQ51720301-CF52953C-AF7F-4E98-BCCE-996B9BB78353
P2860
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pharmacokinetics, efficacy, an ...... ïve and -experienced patients.
@ast
Pharmacokinetics, efficacy, an ...... ïve and -experienced patients.
@en
Pharmacokinetics, efficacy, an ...... ïve and -experienced patients.
@nl
type
label
Pharmacokinetics, efficacy, an ...... ïve and -experienced patients.
@ast
Pharmacokinetics, efficacy, an ...... ïve and -experienced patients.
@en
Pharmacokinetics, efficacy, an ...... ïve and -experienced patients.
@nl
prefLabel
Pharmacokinetics, efficacy, an ...... ïve and -experienced patients.
@ast
Pharmacokinetics, efficacy, an ...... ïve and -experienced patients.
@en
Pharmacokinetics, efficacy, an ...... ïve and -experienced patients.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacokinetics, efficacy, an ...... ïve and -experienced patients.
@en
P2093
Andrew Hill
Diego Miralles
Marta Boffito
P2860
P304
P356
10.1310/HCT0906-418
P577
2008-11-01T00:00:00Z